Press releases
- Ligand to Acquire APEIRON Biologics AG for $100 Million
- Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years
- Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
- Ligand to Participate in Upcoming Investor Conferences
- Ligand Reports First Quarter 2024 Financial Results
- Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
More ▼
Key statistics
On Friday, Ligand Pharmaceuticals Inc (LGNDZ:PKC) closed at 0.0035, -27.08% below its 52-week high of 0.0048, set on Dec 14, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.0024 |
---|---|
High | 0.0035 |
Low | 0.0024 |
Bid | -- |
Offer | -- |
Previous close | 0.0035 |
Average volume | 31.75k |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Jul 19 2024 20:57 BST.
More ▼